SCHEMBL10125819

SCHEMBL10125819

Cc1cc(-c2ccccc2)c2nc(-c3ccc(-c4ccc(-c5nc6ccccc6o5)cc4)cc3)c(-c3ccccc3)nc2c1-c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 9/20 0.46
RAB9A P51151 7/20 0.46
KDM4E B2RXH2 6/20 0.46
HPGD P15428 6/20 0.46
SMN1; SMN2 Q16637 6/20 0.46
CASP3 P42574 3/20 0.46
SENP7 Q9BQF6 3/20 0.46
SENP6 Q9GZR1 3/20 0.46
SENP8 Q96LD8 2/20 0.46
POLB P06746 1/20 0.46
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
ATM Q13315 1/20 0.45
ALDH1A1 P00352 6/20 0.45
HSD17B10 Q99714 4/20 0.45
MAPT P10636 3/20 0.45
USP2 O75604 2/20 0.45
HCRTR1 O43613 2/20 0.45
TSHR P16473 1/20 0.45
MAPK1 P28482 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10126000 1.00 NPC1 (0.46) NPC1RAB9AKDM4EHPGDSMN1; SMN2
SCHEMBL10125940 0.86 NPC1 (0.49) NPC1RAB9AKDM4EHPGDSMN1; SMN2
SCHEMBL10126002 0.86 NPC1 (0.42) NPC1RAB9AKDM4EHPGDSMN1; SMN2
SCHEMBL10125818 0.86 NPC1 (0.42) NPC1RAB9AKDM4EHPGDSMN1; SMN2
SCHEMBL10125840 0.84 NPC1 (0.51) NPC1RAB9AKDM4EHPGDSMN1; SMN2
SCHEMBL12721717 0.84 RAB9A (0.48) NPC1RAB9AKDM4EHPGDSMN1; SMN2
SCHEMBL12721980 0.84 RAB9A (0.48) NPC1RAB9AKDM4EHPGDSMN1; SMN2
SCHEMBL10125986 0.84 NPC1 (0.55) NPC1RAB9AKDM4EHPGDSMN1; SMN2
SCHEMBL10125801 0.84 NPC1 (0.55) NPC1RAB9AKDM4EHPGDSMN1; SMN2
SCHEMBL10125792 0.84 NPC1 (0.55) NPC1RAB9AKDM4EHPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119259-B2 Quinoxaline derivative, and light-emitting element and electronic device using the same SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2012-02-21 US disclosed
US-8119259-B2 Quinoxaline derivative, and light-emitting element and electronic device using the same SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2012-02-21 US disclosed
US-20090140642-A1 Quinoxaline Derivative, and Light-Emitting Element and Electronic Device Using the Same SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2009-06-04 US disclosed
US-20090140642-A1 Quinoxaline Derivative, and Light-Emitting Element and Electronic Device Using the Same SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2009-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090140642-A1 Quinoxaline Derivative, and Light-Emitting Element and Electronic Device Using the Same NDUFA11, NDUFA9, NDUFA12 NPC1 4763/4885RAB9A 1141/4885KDM4E 2216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.